Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Glioblastoma Multiforme Drugs Market $2.9 Billion by 2031

The global Glioblastoma multiforme drugs market expected to reach $2.9 billion by 2031, expanding at a double-digit CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases, and a strong pipeline of new products.

  • A few agents have been approved by the US FDA for the treatment of high-grade gliomas following orphan drug designation, but most have failed to reach the market.
    • However, a few patients may have benefited from receiving developmental agents within clinical trials. Biomarkers for selection of these patients may result in more success in the field of personalized medicine.
  • The number of orphan drug designations seems to keep increasing, and cancer drugs represent the majority as compared with drugs for more traditional rare diseases. This may be seen as an indicator of the success of the Orphan Drug Act, which was initiated in 1983.
    • However, the overall huge expenses associated with most of these agents will require strict health planning and evidence-based guidelines.
Global Glioblastoma Multiforme Drugs Market

Brain and other nervous system cancer is the 10th leading cause of death for men and women. Globally, over 241,000 people die each year as a result of brain or nervous system cancer, with GBM being the most common form of the disease.

  • Glioblastoma multiforme (GBM) has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors. Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults.
    • The incidence of GBM in the U.S. and Europe is 2-3 per 100,000. By definition, an orphan disease is one affecting 200,000 persons in the USA (one in every 1,500). In Europe, the definition is a bit narrower, with fewer than five in 10,000 (one in every 2,000) people affected.
  • Glioblastoma is the most common primary malignant form of brain cancer. Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment.
    • The standard treatment for glioblastoma is surgery. The choice of drug therapy for glioblastoma is still limited to a handful of compounds.
  • The mainstay of treatment for GBMs is surgery, followed by radiation and chemotherapy.
    • More recently, nanomedicine  (Nanocell, which is under development by EnGeneIC and Gold Nanoparticles, which are under development by Midatech Pharma) has contributed to new directions in drug development, discovery, and delivery for treating malignant brain tumors.

Given the limitation of all current therapeutics (surgery, chemotherapy and/or radiation), development of novel approaches to treating glioblastoma remains a great unmet need.

The global Glioblastoma multiforme drugs market report provides market size ($million 2021 to 2031), market share, growth trends and forecast (CAGR%, 2024 to 2031).

The global Glioblastoma multiforme treatment market segmented by product [Avastin (bevacizumab), Temodar (temozolomide), BiCNU/Gliadel Wafer (carmustine)]; clinical pipeline analysis [targeted therapy (TRC-105), gene therapy (VB-111, TOCA 511), immunotherapy [DCVax-Brain, Rindopepimut (CDX-110), ICT-107, Trivax (AV00113)], other therapies and geography.

  • Currently, Merck & Co.’s temzolomide is the preferred FDA-approved chemotherapeutic agent for glioblastoma. Bevacizumab (Avastin), a drug targeting vascular endothelial growth factor (VEGF-A), was suggested as an early-stage trial of targeted therapy for brain cancer.
    • Roche’s Avastin is an anti-angiogenic drug that interferes with the development of blood vessels essential to tumor growth and invasiveness.
      • The FDA granted accelerated approval for bevacizumab, based on its efficacy in treating recurrent glioblastoma.
        • Bevacizumab, a humanized monoclonal antibody targeted to vascular endothelial growth factor (VEGF), received orphan drug designation for the treatment of glioma in 2006.
    • Arbor Pharmaceuticals’ Carmustine drug Gliadel Wafer (BiCNU) is a surgical implant used in the post-operative GBM treatment.
  • The Temodar (TMZ, a methylating agent) drug segment accounted for the largest share of the global market, while bevacizumab (Avastin) was the fastest growing segment over the forecast period.
    • Temozolomide remains the backbone of therapy across all treatment settings. Incident cases of glioblastoma are forecast to increase by 23% during the forecast period.
      • Temozolomide, an orally administered imidazotetrazine derivative, received initial orphan drug designation in 1998 for the treatment of recurrent malignant glioma.
        • Temodar’s future lies in drug combinations, while Avastin will be impacted by biosimilars and pipeline therapies. 
  • Celldex Therapeutics’s Rindopepimut (CDX-110), and Northwest Biotherapeutics’ DCVAx-L vaccines are in the development stages. 
  • Innovative immunotherapies and gene therapies look to serve critically unmet needs in the glioblastoma market.
  • Glioblastoma multiforme is a high-risk space, considering all of the past trial failures, but it also offers rewards for sponsors that succeed in even marginal improvements and researchers are hopeful about the potential of checkpoint inhibitors.
  • GBM treatments that are under development include:
    • Therapies targeting specific parts of the tumor (Mibrefadil, Aldoxorubicin, Val-083, ANG-1005, Afatinib, CBL0137).
    • Drugs against angiogenesis (Altiratinib, MLN518, SapC-DOPS, VB-111, Enzastaurin, TC-A237, AZD2171).
    • A kinase inhibitor (GDC-0084)
    • Immunotherapies such as vaccines (Rindopepimut, SurVaxM, Prophage, Gliovac, IMA950, DCVax-L), antibodies (Depatux-M, Asunercept, MEDI-3617 and MEDI-575), check point inhibitors (NOX-A12).
    • Nanotherapies (Nanocell, AuNP)
    • miRNA targeting (TargoMIR)
    • Glioma stem cell targeting (ICT-107)
    • Gene Therapy (TOCA511)
    • Virus (ParvOryx)

The global glioblastoma multiforme drugs market research report is divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America region accounted for the largest share of the global GBM market, followed by the Asia Pacific region. Prevalence rate is highest is Australia, although China had the largest number of total cases for GBM.

The global glioblastoma multiforme treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global glioblastoma multiforme treatment market market and included in this report are Agenus, Inc., AROG Pharmaceuticals, Inc., Azurity Pharmaceuticals, Inc. (Arbor Pharmaceuticals, Inc.), Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG (F. Hoffman-La Roche AG), and VBI Vaccines, Inc. (FDS Pharma ASS).

  • Product
    • Avastin (Bevacizumab)
    • Temodar (Temozolomide/TMZ)
    • Gliadel Wafer / Carmustine (BiCNU)
  • Pipeline Analysis
    • Targeted Therapy (TRC-105)
    • Gene Therapy (VB-111, TOCA 511/FC)
    • Immunotherapy [DCVax-Brain, Rindopepimut (CDX-110), ICT-107, Trivax (AV00113)]
    • Other Therapies
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Agenus, Inc.
    • AROG Pharmaceuticals, Inc.
    • Azurity Pharmaceuticals, Inc. (Arbor Pharmaceuticals, Inc.)
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Roche Holding AG (F. Hoffman-La Roche AG)
    • VBI Vaccines, Inc. (FDS Pharma ASS)

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com